Free Trial
NASDAQ:APRE

Aprea Therapeutics (APRE) Stock Price, News & Analysis

Aprea Therapeutics logo
$1.66 -0.04 (-2.35%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.70 +0.04 (+2.11%)
As of 08/1/2025 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Aprea Therapeutics Stock (NASDAQ:APRE)

Key Stats

Today's Range
$1.65
$1.85
50-Day Range
$1.60
$2.08
52-Week Range
$1.41
$5.01
Volume
42,900 shs
Average Volume
48,895 shs
Market Capitalization
$9.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50
Consensus Rating
Buy

Company Overview

Aprea Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

APRE MarketRank™: 

Aprea Therapeutics scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aprea Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aprea Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Aprea Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aprea Therapeutics are expected to grow in the coming year, from ($2.55) to ($0.95) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aprea Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aprea Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aprea Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Aprea Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.31% of the float of Aprea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aprea Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aprea Therapeutics has recently decreased by 20.10%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Aprea Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aprea Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.31% of the float of Aprea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aprea Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aprea Therapeutics has recently decreased by 20.10%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    2 people have added Aprea Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aprea Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.63% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 34.19% of the stock of Aprea Therapeutics is held by institutions.

  • Read more about Aprea Therapeutics' insider trading history.
Receive APRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APRE Stock News Headlines

Aprea Therapeutics Inc (APRE) - Investing.com
Aprea Therapeutics, Inc. (APRE) - Yahoo Finance
Ex-Hedge Fund Manager Uncovers $100 Trillion Land Shift
Trump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to unlock federal lands, oil reserves, and buried minerals... all for profit. Trump's team is already executing the orders... and Wall Street legend Whitney Tilson is stepping forward to show you how to position before the deadline.
See More Headlines

APRE Stock Analysis - Frequently Asked Questions

Aprea Therapeutics' stock was trading at $3.29 on January 1st, 2025. Since then, APRE shares have decreased by 49.5% and is now trading at $1.66.

Aprea Therapeutics, Inc. (NASDAQ:APRE) released its earnings results on Wednesday, May, 14th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.01. The business earned $0.16 million during the quarter. Aprea Therapeutics had a negative net margin of 1,095.02% and a negative trailing twelve-month return on equity of 68.39%.

Aprea Therapeutics's stock reverse split before market open on Monday, February 13th 2023.The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Aprea Therapeutics (APRE) raised $52 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO.

Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aprea Therapeutics investors own include Tesla (TSLA), HubSpot (HUBS), Netflix (NFLX), Adverum Biotechnologies (ADVM), Biogen (BIIB), Sarepta Therapeutics (SRPT) and Corbus Pharmaceuticals (CRBP).

Company Calendar

Last Earnings
5/14/2025
Today
8/02/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:APRE
CIK
1781983
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$11.00
Potential Upside/Downside
+833.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.37)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.96 million
Net Margins
-1,095.02%
Pretax Margin
-1,095.02%
Return on Equity
-68.39%
Return on Assets
-55.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.90
Quick Ratio
5.90

Sales & Book Value

Annual Sales
$1.50 million
Price / Sales
6.12
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.55 per share
Price / Book
0.47

Miscellaneous

Outstanding Shares
5,530,000
Free Float
4,777,000
Market Cap
$9.18 million
Optionable
No Data
Beta
1.29
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:APRE) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners